Skip to main content

Table 2 Comparison of the main adverse events between the two groups

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

  CMBs group n = 110 non-CMBs group n = 122 t or χ2 P value
Event-free time (months) 21.4 ± 12.7 23.4 ± 14.0 −1.101 0.272
CH events (%) 18 (16.4) 13 (10.7) 1.628 0.202
All-cause death (%) 14 (12.7) 13 (10.7) 0.241 0.623